These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35107743)

  • 1. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy.
    Fattahi S; Khalifehzadeh-Esfahani Z; Mohammad-Rezaei M; Mafi S; Jafarinia M
    Immunol Res; 2022 Jun; 70(3):269-275. PubMed ID: 35107743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19.
    Basile MS; Cavalli E; McCubrey J; Hernández-Bello J; Muñoz-Valle JF; Fagone P; Nicoletti F
    Drug Discov Today; 2022 Mar; 27(3):848-856. PubMed ID: 34763066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients.
    Abu-Eid R; Ward FJ
    Immunol Lett; 2021 Dec; 240():1-8. PubMed ID: 34562551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
    Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can We Use mTOR Inhibitors for COVID-19 Therapy?
    Aneva IY; Habtemariam S; Banach M; Sil PC; Sarkar K; Sahebnasagh A; Kamal MA; Khayatkashani M; Kashani HRK
    Comb Chem High Throughput Screen; 2022; 25(11):1805-1808. PubMed ID: 34847842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of possible pivotal mechanisms of Genistein as a potential phytochemical against SARS-CoV-2 infection: A hypothesis.
    Jafari A; Esmaeilzadeh Z; Khezri MR; Ghasemnejad-Berenji H; Pashapour S; Sadeghpour S; Ghasemnejad-Berenji M
    J Food Biochem; 2022 Oct; 46(10):e14345. PubMed ID: 35866873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19.
    Mashayekhi-Sardoo H; Hosseinjani H
    J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):17-25. PubMed ID: 34218545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.
    Mohankumar V; Dhanushkodi NR; Raju R
    Biochem Biophys Res Commun; 2011 Mar; 406(2):262-7. PubMed ID: 21316343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
    Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
    J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
    Chen Z; Yang L; Liu Y; Tang A; Li X; Zhang J; Yang Z
    Mol Cell Biochem; 2014 Jan; 385(1-2):169-77. PubMed ID: 24072614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
    Cao X; Kambe F; Moeller LC; Refetoff S; Seo H
    Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
    Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ
    J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization.
    Thaa B; Biasiotto R; Eng K; Neuvonen M; Götte B; Rheinemann L; Mutso M; Utt A; Varghese F; Balistreri G; Merits A; Ahola T; McInerney GM
    J Virol; 2015 Nov; 89(22):11420-37. PubMed ID: 26339054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells.
    Appelberg S; Gupta S; Svensson Akusjärvi S; Ambikan AT; Mikaeloff F; Saccon E; Végvári Á; Benfeitas R; Sperk M; Ståhlberg M; Krishnan S; Singh K; Penninger JM; Mirazimi A; Neogi U
    Emerg Microbes Infect; 2020 Dec; 9(1):1748-1760. PubMed ID: 32691695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.
    Kindrachuk J; Ork B; Hart BJ; Mazur S; Holbrook MR; Frieman MB; Traynor D; Johnson RF; Dyall J; Kuhn JH; Olinger GG; Hensley LE; Jahrling PB
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1088-99. PubMed ID: 25487801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PI3K/Akt/mTOR signaling in dose-dependent biphasic effects of glycine on vascular development.
    Tsuji-Tamura K; Sato M; Fujita M; Tamura M
    Biochem Biophys Res Commun; 2020 Aug; 529(3):596-602. PubMed ID: 32736679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.